27 results on '"D. Pouessel"'
Search Results
2. Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A study of the EAU Young Academic Urologists urothelial carcinoma working group
3. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
4. Résultats oncologiques des patients présentant une atteinte ganglionnaire à la suite d’une chimiothérapie néoadjuvante et d’une cystectomie totale pour un cancer de la vessie infiltrant le muscle : une étude observationnelle multicentrique du groupe de travail sur le carcinome urothélial de l’eau young academic urologists (YAU)
5. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
6. 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
7. 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
8. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
9. LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
10. 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
11. 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
12. High level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
13. FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
14. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
15. Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium
16. Nouvelles hormonothérapies dans le cancer de la prostate
17. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
18. Stratégies périopératoires dans les carcinomes urothéliaux de vessie infiltrant le muscle
19. Séminome de stade I, faut-il enterrer la radiothérapie ?
20. Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales)
21. 7021 POSTER Multidisciplinary Management of Castration Resistant Prostate Cancer (CRPC) in France – a Survey Comparing Practices and Assessing Collaboration Between Urologists and Oncologists
22. Poussées de dermatomyosite associées à des cancers différents chez un même malade
23. Thérapeutiques ciblées dans la neurofibromatose 1 : les premières avancées
24. Combined Chemoradiation Therapy With Gemcitabine and Cisplatinum for Organ Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial
25. Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)
26. Cancérologie - Caractéristiques des métastatses hépatiques de cancer primitif inconnu
27. Syndrome de Good et pneumopathie à cytomégalovirus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.